These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 20933604)

  • 1. Use of calcium channel blockers for glaucoma.
    Araie M; Mayama C
    Prog Retin Eye Res; 2011 Jan; 30(1):54-71. PubMed ID: 20933604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A placebo-controlled 3-year study of a calcium blocker on visual field and ocular circulation in glaucoma with low-normal pressure.
    Koseki N; Araie M; Tomidokoro A; Nagahara M; Hasegawa T; Tamaki Y; Yamamoto S
    Ophthalmology; 2008 Nov; 115(11):2049-57. PubMed ID: 18672290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical flunarizine reduces IOP and protects the retina against ischemia-excitotoxicity.
    Osborne NN; Wood JP; Cupido A; Melena J; Chidlow G
    Invest Ophthalmol Vis Sci; 2002 May; 43(5):1456-64. PubMed ID: 11980861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcium channel blockers and stroke.
    Inzitari D; Poggesi A
    Aging Clin Exp Res; 2005 Aug; 17(4 Suppl):16-30. PubMed ID: 16640170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is the medication used to achieve the target intraocular pressure in glaucoma therapy of relevance?--an exemplary analysis on the basis of two beta-blockers.
    Grieshaber MC; Flammer J
    Prog Retin Eye Res; 2010 Jan; 29(1):79-93. PubMed ID: 19733652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status of safety and efficacy of calcium channel blockers in cardiovascular diseases: a critical analysis based on 100 studies.
    Opie LH; Yusuf S; Kübler W
    Prog Cardiovasc Dis; 2000; 43(2):171-96. PubMed ID: 11014332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppressive actions of betaxolol on ionic currents in retinal ganglion cells may explain its neuroprotective effects.
    Hirooka K; Kelly ME; Baldridge WH; Barnes S
    Exp Eye Res; 2000 May; 70(5):611-21. PubMed ID: 10870519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotective properties of calcium-channel blockers.
    Zornow MH; Prough DS
    New Horiz; 1996 Feb; 4(1):107-14. PubMed ID: 8689265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of topical diltiazem on the intraocular pressure in betamethasone-induced ocular hypertensive rabbits.
    Melena J; Santafé J; Segarra J
    J Pharmacol Exp Ther; 1998 Jan; 284(1):278-82. PubMed ID: 9435188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcium channels and their blockers in intraocular pressure and glaucoma.
    Mayama C
    Eur J Pharmacol; 2014 Sep; 739():96-105. PubMed ID: 24291107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia-induced retinal ganglion cell death and the neuroprotective effects of beta-adrenergic antagonists.
    Chen YN; Yamada H; Mao W; Matsuyama S; Aihara M; Araie M
    Brain Res; 2007 May; 1148():28-37. PubMed ID: 17368577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of neuronal damage by calcium channel blockers with antioxidative effects after transient focal ischemia in rats.
    Lukic-Panin V; Kamiya T; Zhang H; Hayashi T; Tsuchiya A; Sehara Y; Deguchi K; Yamashita T; Abe K
    Brain Res; 2007 Oct; 1176():143-50. PubMed ID: 17904110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotection in relation to retinal ischemia and relevance to glaucoma.
    Osborne NN; Ugarte M; Chao M; Chidlow G; Bae JH; Wood JP; Nash MS
    Surv Ophthalmol; 1999 Jun; 43 Suppl 1():S102-28. PubMed ID: 10416754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Differential therapy with calcium antagonists].
    Scholze JE
    Herz; 2003 Dec; 28(8):754-63. PubMed ID: 14689111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of nilvadipine, a calcium antagonist, on rabbit ocular circulation and optic nerve head circulation in NTG subjects.
    Tomita K; Araie M; Tamaki Y; Nagahara M; Sugiyama T
    Invest Ophthalmol Vis Sci; 1999 May; 40(6):1144-51. PubMed ID: 10235547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Calcium antagonists: current and future applications based on new evidence. Effects of calcium channel blockers on oxidative stress].
    Nishiyama A; Nakano D; Hitomi H
    Clin Calcium; 2010 Jan; 20(1):38-44. PubMed ID: 20048432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The dawn of neuroprotective therapy for glaucomatous optic neuropathy].
    Yamamoto T
    Nippon Ganka Gakkai Zasshi; 2001 Dec; 105(12):866-83. PubMed ID: 11802458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Contemporary possibilities and perspectives in the treatment of glaucoma].
    Czepita D
    Ann Acad Med Stetin; 2005; 51(1):27-31. PubMed ID: 16496599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of antiglaucoma drugs on ocular hemodynamics in healthy volunteers.
    Schmetterer L; Strenn K; Findl O; Breiteneder H; Graselli U; Agneter E; Eichler HG; Wolzt M
    Clin Pharmacol Ther; 1997 May; 61(5):583-95. PubMed ID: 9164420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
    Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L
    Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.